Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 806-795-8 | CAS number: 909419-73-4
Endpoint summary
Administrative data
Description of key information
The acute toxicity of the substance was tested in albino mice and Sprague-Dawley rats. The substance was administered to mice (strain nor specified) at doses of 500 and 2000 mg/kg p.o. (3/sex/groups) and 300, 500, and 1000 mg/kg i.p. (3M only).
Rats received doses of 500 and 2000 mg/kg p.o. (3/sex) and 500 and 2000 mg/kg i.p. (3M only).
Drug-related deaths occurred only in male mice at 1000 mg/kg i. p. Sedation was the primary clinical sign with both routes. CNS signs tended to have a more rapid onset and prolonged duration with i. p. dosing. No target organ for toxicity was identified.
LD50's were calculated to be >2000 mg/kg p.o. in both mice and rats and >2000 mg/kg i.p. in rats, and 500-1000 mg/kg i.p. in mice.
This study was not definitive due to the lack of a complete battery of measurements, of control groups, and the small n/group.
The available date are conclusive but not sufficient for the classification of the substance for acute oral toxicity.
To assess dermal toxicity, ziprasidone was applied to intact skin at a single dose of 2000 mg for 24 hrs. Animals (n= 5) were examined 2 days after drug application. In the dermal study, no drug-related mortality or clinical signs or changes in body wt or food consumption were observed, nor were any signs if dermal irritation detected.
The available date are conclusive but not sufficient for the classification of the substance for acute dermal toxicity
Key value for chemical safety assessment
Acute toxicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
Additional information
Justification for classification or non-classification
Oral and dermal LD50's were calculated to be >2000 mg/kg.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
